T1	p 335 357	healthy young subjects
T2	p 431 461	Five groups of 8 subjects each
T3	p 1598 1619	subjects with low HDL
T4	p 1669 1672	the
T5	p 1678 1706	of CETP in atherosclerosis .
T6	i 188 222	cholesteryl ester transfer protein
T7	i 232 253	inhibitor torcetrapib
T8	i 481 519	placebo ( n=2 ) or torcetrapib ( n=6 )
T9	i 1616 1619	HDL
T10	o 14 38	high-density lipoprotein
T11	o 278 324	high-density lipoprotein cholesterol ( HDL-C )
T12	o 613 622	tolerated
T13	o 690 711	of plasma drug levels
T14	o 717 727	inhibition
T15	o 974 976	of
T16	o 1001 1025	Total plasma cholesterol
T17	o 1129 1164	low-density lipoprotein cholesterol
T18	o 1187 1205	Apolipoprotein A-I
T19	o 1345 1361	and triglyceride
T20	o 1379 1401	nonHDL plasma fraction
T21	o 1442 1447	HDL .